Phaseline

Targets › GARP

GARP: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: the race on GARP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ohio State University Comprehensive Cancer CenterAnti-GARP Chimeric Antigen Receptor-T Cells
Anti-GARP CAR-T cell therapy
GARPPhase 1Recurrent Malignant GliomaMay 2027

Conditions

Recurrent Malignant Glioma (1)

Modalities

other (1)

Companies

Ohio State University Comprehensive Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.